, China
/Matheus Natan from Pexels

S&P forecasts slight increase in CCB's NPA ratio

The slow growth will be due to problematic property loans and higher loan ratios.

S&P Global projects China Construction Bank’s (CCB) non-performing asset ratio will inch up to 4.48% in 2024 from 4.40% in 2023, with estimates including forborne and other problem assets.

S&P said that this slow growth will be caused by problematic property loans and higher reported special-mention (SPL) and non-performing (NPL) loan ratios following the new asset classification rules.

ALSO READ: S&P predicts modest capital upkeep for PICC Group amidst market changes

The agency noted that in 2023, CCB reported an unchanged NPL of 1.37% while the SML slipped to 2.44% from 2.50% by end-June. 

On the flip side, CCB’s NPL ratio in 2H2023 rose 88 basis points to 5.64% and property loans remained a small portion of the total loans at 3.6% by end-2023, resulting in a 10.8% loan growth in 2023.

S&P Global expects tighter NIMs to continue to constrain profitability amidst CCB’s ongoing shift to corporate sectors due to consecutive cuts in interest rates and the government’s push for banks to lower their lending rates to support the real economy. In 2023, CCB reported a lower NIM of 1.70%, down from 2.01% a year ago.

Prudential, StanChart memperkuat 25 Tahun kemitraan bancassurance

Mereka memiliki kemitraan bancassurance terlama di Singapura dan Asia.

MSIG Asia dan RiskPoint mempertaruhkan asuransi energi terbarukan

Kawasan Asia-Pasifik berpotensi menarik investasi sebesar $3 triliun dalam pembangkitan listrik hingga 2033.

Kantor pusat Pru Life UK di Manila menerapkan kerja hibrida

Kantor ini memiliki area rekreasi dan kesehatan untuk membantu karyawan menyegarkan diri.

Etiqa meluncurkan produk asuransi takaful pertama di Singapura

Permintaan terhadap produk keuangan Islam dari Timur Tengah dan Asia Tenggara terus meningkat.

Perusahaan asuransi jiwa Singapura bidik pertumbuhan di 2025

Dorongan untuk solusi layanan kesehatan inovatif di tengah inflasi medis menjadi tantangan.